The Asia Pacific Antiplatelet Market would witness market growth of 5.5% CAGR during the forecast period (2023-2030). In the year 2021, the Asia Pacific market's volume surged to 111.9 million Units, showcasing a growth of 4.0% (2019-2022).
The prevalence of antithrombotic/anticoagulant medications, the aging population, an upsurge in thrombotic events, and recent pharmaceutical advancements are some of the main factors driving the market. Antithrombotic agents are substances that prevent blood clotting from forming. Antithrombotic could be used therapeutically for prevention (primary prevention, secondary prevention) or treatment of a hazardous blood clot (acute thrombus).
The demand for antiplatelet pharmaceuticals is not limited to developed nations but is also witnessed in developing countries, which is anticipated to propel market growth. Additionally, the market for antiplatelets is expanding due to increased government initiatives for cardiovascular disorders, including stroke. Under the National Programme for the Prevention and Control of Cancer, Cardiovascular Diseases, Diabetes, and Stroke (NPCDCS), the Department of Health & Family Welfare, Government of India, provides technical and financial support to the States/UTs. Campaigns for awareness, screening programs, and subsidized access to drugs are frequently included in these activities.
As per International Trade Administration, in 2018, China's healthcare sector exhibited continuous, robust expansion and dynamic regulatory shifts. The sector for medical devices in China reached approximately USD 70 billion. The demand for medical devices has maintained double-digit growth for over a decade, making it one of China's fastest-growing markets. Over 70% of this expansion had attributable to hospital procurement. In recent years, the Asia Pacific region has seen a considerable rise in research and development (R&D) activities related to antiplatelet therapies and cardiovascular medicine. Hence, with the expanding disease burden and healthcare sector, the market will grow throughout the forecast period.
The China market dominated the Asia Pacific Antiplatelet Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $347.9 Million by 2030. The Japan market is registering a CAGR of 4.8% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 6.1% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Oral, and Injectable. Based on Drug Class, the market is segmented into Adenosine diphosphate (ADP) Receptor Inhibitors, Irreversible Inhibitors Cyclooxygenase, and Others. Based on Distribution Channel, the market is segmented into Drug store & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cipla Limited, Glenmark Pharmaceuticals Limited, Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Eli Lilly And Company, Otsuka Pharmaceutical Co., Ltd., Sanofi S.A. , Lupin Limited and Chiesi Farmaceutici S.p.A.
The prevalence of antithrombotic/anticoagulant medications, the aging population, an upsurge in thrombotic events, and recent pharmaceutical advancements are some of the main factors driving the market. Antithrombotic agents are substances that prevent blood clotting from forming. Antithrombotic could be used therapeutically for prevention (primary prevention, secondary prevention) or treatment of a hazardous blood clot (acute thrombus).
The demand for antiplatelet pharmaceuticals is not limited to developed nations but is also witnessed in developing countries, which is anticipated to propel market growth. Additionally, the market for antiplatelets is expanding due to increased government initiatives for cardiovascular disorders, including stroke. Under the National Programme for the Prevention and Control of Cancer, Cardiovascular Diseases, Diabetes, and Stroke (NPCDCS), the Department of Health & Family Welfare, Government of India, provides technical and financial support to the States/UTs. Campaigns for awareness, screening programs, and subsidized access to drugs are frequently included in these activities.
As per International Trade Administration, in 2018, China's healthcare sector exhibited continuous, robust expansion and dynamic regulatory shifts. The sector for medical devices in China reached approximately USD 70 billion. The demand for medical devices has maintained double-digit growth for over a decade, making it one of China's fastest-growing markets. Over 70% of this expansion had attributable to hospital procurement. In recent years, the Asia Pacific region has seen a considerable rise in research and development (R&D) activities related to antiplatelet therapies and cardiovascular medicine. Hence, with the expanding disease burden and healthcare sector, the market will grow throughout the forecast period.
The China market dominated the Asia Pacific Antiplatelet Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $347.9 Million by 2030. The Japan market is registering a CAGR of 4.8% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 6.1% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Oral, and Injectable. Based on Drug Class, the market is segmented into Adenosine diphosphate (ADP) Receptor Inhibitors, Irreversible Inhibitors Cyclooxygenase, and Others. Based on Distribution Channel, the market is segmented into Drug store & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cipla Limited, Glenmark Pharmaceuticals Limited, Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Eli Lilly And Company, Otsuka Pharmaceutical Co., Ltd., Sanofi S.A. , Lupin Limited and Chiesi Farmaceutici S.p.A.
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration (Volume, Million Units, USD Million, 2019-2030)- Oral
- Injectable
- Adenosine diphosphate (ADP) Receptor Inhibitors
- Irreversible Inhibitors Cyclooxygenase
- Others
- Drug store & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Cipla Limited
- Glenmark Pharmaceuticals Limited
- Bayer AG
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Eli Lilly And Company
- Otsuka Pharmaceutical Co., Ltd.
- Sanofi S.A.
- Lupin Limited
- Chiesi Farmaceutici S.p.A
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Antiplatelet Market by Route of Administration
Chapter 5. Asia Pacific Antiplatelet Market by Drug Class
Chapter 6. Asia Pacific Antiplatelet Market by Distribution Channel
Chapter 7. Asia Pacific Antiplatelet Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Cipla Limited
- Glenmark Pharmaceuticals Limited
- Bayer AG
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Eli Lilly And Company
- Otsuka Pharmaceutical Co., Ltd.
- Sanofi S.A.
- Lupin Limited
- Chiesi Farmaceutici S.p.A
Methodology
LOADING...
